retatrutide ly3437943 triple agonist glp-1 gip glucagon Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% GLP-3 (R) - Triple GIP

The level of secreted incretin of diabetics commonly resembles that of healthy people, yet the number of incretin receptors is substantially lower

Best protein sources for GLP-1 users Not all protein sources work equally well when your digestive system runs slower than usual

McIntyre, MD: GLP-1 agonists for psychiatry

Injectable Wegovy produced an average weight loss of around 15 percent in major trials, while tirzepatide, sold as Zepbound for obesity, has produced around 20 percent or more weight loss depending on dose and population

Keep a headache diary that tracks frequency, severity, duration, associated symptoms, and potential triggers